Cardiff Oncology (CRDF) Change in Accured Expenses (2011 - 2025)

Cardiff Oncology has reported Change in Accured Expenses for 15 years, with the latest figure at $940000.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 4.68% year-over-year to $940000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 26.23% YoY) and the FY2025 annual result came in at $2.2 million, down 26.23% from the prior year.
• Change in Accured Expenses improved to $940000.0 in Q4 2025 per CRDF's latest filing, from -$2.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.3 million in Q2 2025 and troughed at -$2.0 million in Q3 2025.
• A 5-year average of $457631.6 and a median of $203000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses jumped 5595.83% in 2022, then plunged 196000.0% in 2025.
• Over 5 years, Change in Accured Expenses stood at $1.5 million in 2021, then slumped by 188.25% to -$1.4 million in 2022, then jumped by 202.63% to $1.4 million in 2023, then plunged by 35.99% to $898000.0 in 2024, then advanced by 4.68% to $940000.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $940000.0, -$2.0 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.